Gut Microbiota Dysbiosis in Opioid Use Disorders: Implications for Clinical Symptoms and Relapse Rate.

Assiut University

Status: Not yet enrolling

Conditions: Opioid Use Disorder; Opioid Use; Opioid Dependence

Treatments: Diagnostic Test: stool analysis

Study type: Observational

Funder types: Other

Identifiers

NCT06231849

gut microbiota in opioid use

Details and patient eligibility

About

This study will aim to investigate the gut microbiota in Egyptian patients with opioid use disorders and correlate microbiota bacterial abundance with clinical data.

Full description

Addiction is defined as a chronic, relapsing disorder characterized by compulsive drug seeking and use despite adverse consequences. Pathological substance use disorders represent a major public health crisis with limited effective treatment options. Although the gut and brain are separate organs, they communicate with each other via trillions of intestinal bacteria that collectively make up one's gut microbiome. Findings from both humans and animals support a critical role of gut microbes in regulating brain function, mood, and behavior. Gut bacteria influence neural circuits that are notably affected in addiction-related behaviors. These include circuits involved in stress, reward, and motivation, with substance use influencing gut microbial abnormalities, suggesting significant gut-brain interactions in drug addiction.

The investigator will discuss this role of gut microbiome in Assuit university hospital to see how the pathogenesis can be altered of drug addiction.

Enrollment: 52 estimated patients

Sex: Male

Ages: 20 to 35 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Clinical and laboratory diagnosis of substance missuse.
2. Must be encountering withdrawal symptoms for the first time.

Exclusion criteria

1. An intelligence quotient (IQ) below 70.
2. Gastrointestinal diseases.

Trial design

52 participants in 2 patient groups

normal subjects without opioid intoxications.

Description:

1. Individuals of male gender aged between 20 to 35 years old

individuals with opioid use disorders.

Description:

Individuals of male gender aged between 20 to 35 years old with opioid use disorders.

Treatment:

Diagnostic Test: stool analysis